利用单细胞基因组学预测erenumab不良事件。 - Suppr

Suppr

超能文献

Predicting erenumab adverse events with single-cell genomics.

作者信息

Vgontzas Angeliki, Renthal William

机构信息

Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.

出版信息

Lancet. 2020 Jul 11;396(10244):95-96. doi: 10.1016/S0140-6736(19)32952-6.

DOI:10.1016/S0140-6736(19)32952-6

PMID:32653068

Abstract

摘要

相似文献

Predicting erenumab adverse events with single-cell genomics.

Lancet. 2020 Jul 11;396(10244):95-96. doi: 10.1016/S0140-6736(19)32952-6.

Erenumab Side Effects.

Headache. 2019 Jul;59(7):1088-1089. doi: 10.1111/head.13589.

Erenumab: First Global Approval.

Drugs. 2018 Jul;78(11):1157-1161. doi: 10.1007/s40265-018-0944-0.

Cardio- and cerebrovascular safety of erenumab, a monoclonal antibody targeting CGRP receptors - important studies on human isolated arteries.

Cephalalgia. 2019 Dec;39(14):1731-1734. doi: 10.1177/0333102419877169. Epub 2019 Sep 16.

In brief: Erenumab (Aimovig) hypersensitivity.

Med Lett Drugs Ther. 2019 Mar 25;61(1568):48.

Long-term tolerability and nonvascular safety of erenumab, a novel calcitonin gene-related peptide receptor antagonist for prevention of migraine: A pooled analysis of four placebo-controlled trials with long-term extensions.

Cephalalgia. 2019 Dec;39(14):1798-1808. doi: 10.1177/0333102419888222. Epub 2019 Nov 10.

A phase IV clinical trial of gastrointestinal motility in adult patients with migraine before and after initiation of a calcitonin gene-related peptide ligand (galcanezumab) or receptor (erenumab) antagonist.

Headache. 2022 Oct;62(9):1164-1176. doi: 10.1111/head.14390. Epub 2022 Sep 16.

Recommendations on the Use of Anti-CGRP Monoclonal Antibodies in Children and Adolescents.

Headache. 2018 Nov;58(10):1658-1669. doi: 10.1111/head.13414. Epub 2018 Oct 15.

CGRP Antagonists for the Treatment of Chronic Migraines: a Comprehensive Review.

Curr Pain Headache Rep. 2019 Mar 14;23(5):29. doi: 10.1007/s11916-019-0768-y.

Erenumab (Aimovig) for Migraine Prophylaxis in Adults.

Am Fam Physician. 2019 Jun 15;99(12):781-782.

引用本文的文献

Population-scale identification of differential adverse events before and during a pandemic.

Nat Comput Sci. 2021 Oct;1(10):666-677. doi: 10.1038/s43588-021-00138-4. Epub 2021 Oct 5.

Ten open questions in migraine prophylaxis with monoclonal antibodies blocking the calcitonin-gene related peptide pathway: a narrative review.

J Headache Pain. 2023 Aug 1;24(1):99. doi: 10.1186/s10194-023-01637-7.

Erenumab for Migraine Prevention in a 1-Year Compassionate Use Program: Efficacy, Tolerability, and Differences Between Clinical Phenotypes.

Front Neurol. 2021 Dec 10;12:805334. doi: 10.3389/fneur.2021.805334. eCollection 2021.

Treatment with the monoclonal calcitonin gene-related peptide receptor antibody erenumab: A real-life study.

Eur J Neurol. 2021 Dec;28(12):4194-4203. doi: 10.1111/ene.15075. Epub 2021 Sep 7.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Predicting erenumab adverse events with single-cell genomics.

作者信息

Vgontzas Angeliki, Renthal William

机构信息

Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.

出版信息

Lancet. 2020 Jul 11;396(10244):95-96. doi: 10.1016/S0140-6736(19)32952-6.

DOI:10.1016/S0140-6736(19)32952-6

PMID:32653068

Abstract

摘要

相似文献

Predicting erenumab adverse events with single-cell genomics.

Lancet. 2020 Jul 11;396(10244):95-96. doi: 10.1016/S0140-6736(19)32952-6.

Erenumab Side Effects.

Headache. 2019 Jul;59(7):1088-1089. doi: 10.1111/head.13589.

Erenumab: First Global Approval.

Drugs. 2018 Jul;78(11):1157-1161. doi: 10.1007/s40265-018-0944-0.

Cardio- and cerebrovascular safety of erenumab, a monoclonal antibody targeting CGRP receptors - important studies on human isolated arteries.

Cephalalgia. 2019 Dec;39(14):1731-1734. doi: 10.1177/0333102419877169. Epub 2019 Sep 16.

In brief: Erenumab (Aimovig) hypersensitivity.

Med Lett Drugs Ther. 2019 Mar 25;61(1568):48.

Cephalalgia. 2019 Dec;39(14):1798-1808. doi: 10.1177/0333102419888222. Epub 2019 Nov 10.

Headache. 2022 Oct;62(9):1164-1176. doi: 10.1111/head.14390. Epub 2022 Sep 16.

Recommendations on the Use of Anti-CGRP Monoclonal Antibodies in Children and Adolescents.

Headache. 2018 Nov;58(10):1658-1669. doi: 10.1111/head.13414. Epub 2018 Oct 15.

CGRP Antagonists for the Treatment of Chronic Migraines: a Comprehensive Review.

Curr Pain Headache Rep. 2019 Mar 14;23(5):29. doi: 10.1007/s11916-019-0768-y.

Erenumab (Aimovig) for Migraine Prophylaxis in Adults.

Am Fam Physician. 2019 Jun 15;99(12):781-782.

引用本文的文献

Population-scale identification of differential adverse events before and during a pandemic.

Nat Comput Sci. 2021 Oct;1(10):666-677. doi: 10.1038/s43588-021-00138-4. Epub 2021 Oct 5.

Ten open questions in migraine prophylaxis with monoclonal antibodies blocking the calcitonin-gene related peptide pathway: a narrative review.

J Headache Pain. 2023 Aug 1;24(1):99. doi: 10.1186/s10194-023-01637-7.

Erenumab for Migraine Prevention in a 1-Year Compassionate Use Program: Efficacy, Tolerability, and Differences Between Clinical Phenotypes.

Front Neurol. 2021 Dec 10;12:805334. doi: 10.3389/fneur.2021.805334. eCollection 2021.

Treatment with the monoclonal calcitonin gene-related peptide receptor antibody erenumab: A real-life study.

Eur J Neurol. 2021 Dec;28(12):4194-4203. doi: 10.1111/ene.15075. Epub 2021 Sep 7.